| Literature DB >> 31109692 |
Mariana de Pauli Paglioni1, Anna Luíza Damaceno Araújo1, Lady Paola Aristizábal Arboleda1, Natalia Rangel Palmier1, Jéssica Montenegro Fonsêca1, Wagner Gomes-Silva2, Cristhian Camilo Madrid-Troconis3, Felipe Martins Silveira1, Manoela Domingues Martins4, Karina Morais Faria5, Ana Carolina Prado Ribeiro5, Thaís Bianca Brandão5, Marcio Ajudarte Lopes1, Adriana Franco Paes Leme6, César Augusto Migliorati7, Alan Roger Santos-Silva8.
Abstract
Photobiomodulation therapy (PBMT), also known as low-level laser therapy (LLLT), has been increasingly used for the treatment of toxicities related to cancer treatment. One of the challenges for the universal acceptance of PBMT use in cancer patients is whether or not there is a potential for the light to stimulate the growth of residual malignant cells that evaded oncologic treatment, increasing the risk for tumor recurrences and development of a second primary tumor. Current science suggests promising effects of PBMT in the prevention and treatment of breast cancer-related lymphedema and oral mucositis, among other cancer treatment toxicities. Nevertheless, this seems to be the first systematic review to analyze the safety of the use of PBMT for the management of cancer-related toxicities. Scopus, MEDLINE/PubMed, and Embase were searched electronically. A total of 27 articles met the search criteria. Selected studies included the use of PBMT for prevention and treatment of oral mucositis, lymphedema, radiodermatitis, and peripheral neuropathy. Most studies showed that no side effects were observed with the use of PBMT. The results of this systematic review, based on current literature, suggest that the use of PBMT in the prevention and management of cancer treatment toxicities does not lead to the development of tumor safety issues.Entities:
Keywords: Cancer; Cancer treatment toxicities; Laser; Mucositis; Photobiomodulation; Safety; Side effect; Systematic review
Mesh:
Year: 2019 PMID: 31109692 DOI: 10.1016/j.oraloncology.2019.04.004
Source DB: PubMed Journal: Oral Oncol ISSN: 1368-8375 Impact factor: 5.337